Florence Salmon | Global Head Regulatory Cell and Gene Therapies
Roche

Florence Salmon holds a PhD in Molecular and Cellular Biology. She has considerable experience in cell and gene therapies development and regulatory affairs, bringing many of the early cell and gene therapies from the bench to the clinic, and to marketing authorisation. Among others she worked at uniQure on the EU approval of the first AAV-based gene therapy, Glybera, in 2012 and supported the development of several AAV-based gene therapy vectors for various disease areas. At Novartis, she worked on the development and global approvals of Kymriah (first autologous CAR-T) in 2017, Luxturna and Zolgensma, and advised on the development of the cell and gene therapies pipeline. Over the years, she participated in building-up several biotech and start-ups,  and in the development of several new modalities and cell and gene therapies. She is currently Global Head Regulatory
Affairs Cell and Gene Therapies at Roche.